Leukemia


Venclexta® and Low-doses of Cytarabine Effective in Elderly with Acute Myeloid Leukemia (January 26, 2017)

The treatment combination consisting of Venclexta® (venetoclax) plus low-doses of the chemotherapy agent cytarabine appears to be an effective and tolerable treatment regimen for elderly patients with... Continue Reading

Roswell Park Researchers Offer Novel Insight into Genetic Changes Leading to Cancer (January 18, 2017)

Findings may lead to personalized prognostic tests for blood disorders Predisposition to cancer and cancer progression can result from gene mutations that cause elevated rates of genetic damage. Similarly,... Continue Reading

Progress Reported in New Treatments for People with Lymphoma (December 29, 2016)

Research and pharmaceutical executives unveil encouraging clinical trial data at the annual meeting of the American Society of Hematology. Twenty-two years ago, Dr. Gary Gordon, Ph.D., vice president of... Continue Reading

FDA Grants Iclusig® Expanded Approval for CML (December 14, 2016)

The United States Food and Drug Administration (FDA) has granted Iclusig® (ponatinib) approval to treat all phases of chronic myeloid leukemia (CML) in adults, as well as Philadelphia-chromosome positive... Continue Reading

UCLA Identifies Potential Cancer Treatment with Fewer Side Effects Than Chemotherapy (December 12, 2016)

By Stuart Wolpert, UCLA Asynthetic version of a rare toxin produced by a sea creature appears to hold promise for treating many different types of cancer while minimizing the harmful side effects of widely... Continue Reading

Duration of Blood Storage Does Not Affect Outcomes for Patients Requiring Blood Transfusions (December 1, 2016)

The length of time that blood is stored prior to a blood transfusion, within normal ranges, does not appear to affect mortality among patients requiring transfusions. These results were recently published... Continue Reading

FDA Priority Review Granted for Midostaurin in Leukemia (November 17, 2016)

The United States Food and Drug Administration (FDA) has granted priority review to PKC412 (midostaurin) in the treatment of newly diagnosed acute myeloid leukemia (AML) with the FLT3 mutation, as well... Continue Reading

Useful Definitions for Chronic Myelogenous Leukemia (CML) (November 16, 2016)

Blood stem cell: An immature cell from which other types of blood cells develop. Bone marrow: The soft, sponge-like tissue in the center of most bones where blood cells are made. Chromosomes: Long strands... Continue Reading

Discovery of Ezh2 May Represent New Treatment Option for Chronic Myelogenous Leukemia (November 3, 2016)

Each year in the United States, approximately 5,000 people are diagnosed with CML. Most cases of CML are characterized by a chromosomal abnormality—the Philadelphia chromosome—in which genetic material... Continue Reading

LLS Launches Groundbreaking Precision Medicine Approach To Treat AML (November 1, 2016)

Going on the offensive against one of the most daunting challenges in cancer, The Leukemia & Lymphoma Society (LLS) announced the launch of a groundbreaking, collaborative clinical trial for acute... Continue Reading

High Up-Front Costs Could Delay Access to Life-Saving Blood Cancer Drugs for Medicare Patients (October 18, 2016)

Significant out-of-pocket costs that cancer patients can face before Medicare insurance drug benefits kick in may delay the patients’ treatment with a novel class of targeted therapies, according to... Continue Reading

Rituxan Improves Survival in Young Adults with Acute Lymphoblastic Leukemia (September 26, 2016)

Acccording to results recently published in the New England Journal of Medicine, young adults with CD20-positive, Philadelphia chromosome  (PH)-negative acute lymphoblastic leukemia (ALL), experience... Continue Reading

Inotuzumab Ozogamicin Improves Progression-Free Survival in Acute Leukemia (September 6, 2016)

The investigative agent, inotuzumab ozogamicin, significantly improves progression-free survival and 2-year survival rates among patients with acute lymphoblastic leukemia that has stopped responding to... Continue Reading

Pass It On: July is National Leukemia and Lymphoma Awareness Month (September 1, 2016)

Leukemia and lymphoma are both hematologic malignancies, meaning that they involve the blood or bone marrow. The American Cancer Society (ACS) estimates that there will be 60,140 new cases of leukemia... Continue Reading

Pracinostat Receives Breakthrough Therapy Designation from FDA for Treatment in Combination with Azacitidine of Patients with Newly Diagnosed Acute Myeloid Leukemia (August 9, 2016)

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for the investigational drug Pracinostat in combination with azacitidine for the treatment of elderly patients with... Continue Reading

FDA Places Hold on a Trial Evaluating Genetically Engineered Immune Cells for Cancer Treatment (July 18, 2016)

The United States Food and Drug Administration (FDA) has placed a hold on a clinical trial, referred to as the ROCKET trial, due to side effects of the treatment that may be associated with 3 patient deaths. Chimeric... Continue Reading

Imbruvica® Effective in Newly Diagnosed and Recurrent Chronic Lymphocytic Leukemia (July 11, 2016)

Imbruvica (ibrutinib) produces long-lasting anti-cancer responses among patients with newly diagnosed chronic lymphocytic leukemia (CLL), as well as those who have received prior therapies. These results... Continue Reading

GlycoMimetics’ GMI-1271 Receives FDA Fast Track Designation for Treatment of Acute Myeloid Leukemia (July 4, 2016)

GlycoMimetics, Inc. has announced that it received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its novel E-selectin antagonist GMI-1271 for treatment of adult patients with... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS